Tag: Drugs and Pharmaceuticals
SET Enterprises launches 340b covered entity suspicious purchase identification service for pharmaceutical and biological manufacturers
PHOENIX, Ariz. /ScoopCloud/ -- SET Enterprises, a leading independent management consulting firm serving the government pricing compliance needs of life sciences manufacturers, today announced the launch of SPI340B℠. This new service offering identifies specific 340B covered entities that exhibit suspicious purchasing patterns that suggest the entire volume of products purchased from pharmaceutical and biotechnology manufacturers may not be dispensed solely to eligible patients of the covered entity.
Divergent CRO Announces Launch of New Contract Research Organization
ATLANTA, Ga. /ScoopCloud/ -- Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.
Trends in Drug Benefit Design Report Released by Pharmaceutical Strategies Group (PSG)
DALLAS, Texas /ScoopCloud/ -- Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the launch of its Trends in Drug Benefit Design Report. The report delivers innovative research on the latest trends in the traditional (non-specialty) drug benefit. Sponsored by Rx Savings Solutions, it outlines the complexities of designing and managing the drug benefit and the cost challenges faced by consumers and plan sponsors alike.
PSG Announces Release of Highly Anticipated ‘Trends in Specialty Drug Benefits Report’
DALLAS, Texas /ScoopCloud/ -- Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the release of its annual Trends in Specialty Drug Benefits report. Delivering visibility into the complexity of the specialty drug landscape, it offers detailed intelligence through proprietary research. PSG has been researching and reporting on drug benefit design for over 10 years.
NEW PRODUCT LAUNCH: Pharmaceutical Strategies Group (PSG) Announces Artemetrx Extend – Revolutionary Drug Management Reporting Tool Offers Powerful User Insights
DALLAS, Texas /ScoopCloud/ -- Artemetrx®, the industry's most preeminent platform for integrated drug cost management, is now even more robust with the launch of its new module, Artemetrx Extend™. With greater insights and analytics, Artemetrx Extend is a custom reporting tool that provides unparalleled data access through its user-friendly platform.
Kalyagen Announces Attendance and Speaking Engagement at 8th Annual Biohacking Conference
Kalyagen -
AUSTIN, Texas /ScoopCloud/ -- Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.
Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines
PFLUGERVILLE, Texas /ScoopCloud/ -- Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo's latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.
Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine
ROCHESTER, Minn. /ScoopCloud/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.
Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies
OKLAHOMA CITY, Okla. /ScoopCloud/ -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.
Geminid Systems Unveils Pharmalite CRM to Boost Remote Engagement of Pharma Field Teams
REDWOOD CITY, Calif. /ScoopCloud/ -- Geminid Systems, Inc. today announced the global rollout of a SaaS super-app that aims to improve pharmaceutical operations by helping field teams easily overcome challenges arising from the ongoing COVID pandemic.
iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal
STONY BROOK, N.Y. /ScoopCloud/ -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.
Kalyagen Announces Release of Free eBook on How to Optimize Health Using Stem Cells
Kalyagen -
AUSTIN, Texas /ScoopCloud/ -- Kalyagen® has announced the release and availability of a free eBook, "The Stemregen Effect - Tapping into the Power of Your Own Stem Cells," which provides an overview of how stem cells are the body's repair system and how STEMREGEN®, a natural stem cell enhancer, has been documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).
Live-Online C. diff. Symposium developed to support and guide patients, families, and caregivers through a C. difficile illness
TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences.
Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health
AUSTIN, Texas /ScoopCloud/ -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.
Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients
BIRMINGHAM, Ala. /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research.
Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device for Vaccines and Pharmaceuticals
AUSTIN, Texas /ScoopCloud/ -- Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEO Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.
Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers
AUSTIN, Texas /ScoopCloud/ -- Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.
Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Kabuki Syndrome
CARY, N.C. /ScoopCloud/ -- Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company's lead drug RSC-57, for the treatment of patients with Kabuki Syndrome.
Kalyagen Announces Launch of ‘Stem the Tide of Time’ Campaign Featuring NBA Hall of Fame Finalist Marques Johnson
Kalyagen -
AUSTIN, Texas /ScoopCloud/ -- Kalyagen is pleased to announce the launch of its "Stem the Tide of Time" social media campaign featuring former UCLA Bruin and Milwaukee Buck All-Star Marques Johnson to promote STEMREGEN;, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).
Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients
Kalyagen -
AUSTIN, Texas /ScoopCloud/ -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure.
EPIC Insurance Brokers & Consultants Acquires Pharmaceutical Strategies Group
SAN FRANCISCO, Calif. /ScoopCloud/ -- EPIC Holdings, Inc. (EPIC) announced today that it has agreed to acquire Pharmaceutical Strategies Group (PSG). The move incorporates the expertise and resources of the nation's largest independent pharmacy benefit consulting firm into EPIC's Employee Benefits Consulting practice.
Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program
AUSTIN, Texas /ScoopCloud/ -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.
Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology
CHRISTIANSBURG, Va. /ScoopCloud/ -- Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology.
NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor
CAMBRIDGE, Mass. /ScoopCloud/ -- NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company's Medical Advisor of Infectious Disease.
US Pharmaceutical Corporation® Introduces Patented Hylafem® pH Vaginal Suppositories Consisting of Boric Acid in a Probiotic Blend
DECATUR, Ga. /ScoopCloud/ -- US Pharmaceutical Corporation, the probiotic and nutritional supplement company, launches Hylafem pH vaginal suppositories, a unique, patented, homeopathic suppository product which efficaciously tackles recurring women's vaginal health issues.
Thar Process Expands into India to Focus on Pharmaceutical Purification Market
PITTSBURGH, Pa. /ScoopCloud/ -- Thar Process, Inc - an American manufacturer of high-tech supercritical CO2 extraction and purification equipment - is proud to announce the signing of a new exclusive distribution deal with YMC India (a subsidiary of YMC Co. Ltd., JAPAN).
A Novel Treatment Approach to Silent Hypoxia in COVID-19 Patients
PARK CITY, Utah /ScoopCloud/ -- Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients' lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties.
ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial
LOS ANGELES, Calif. /ScoopCloud/ -- ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.
Boothwyn Pharmacy in Kennett Square Now Manufacturing Hand Sanitizer
KENNETT SQUARE, Pa. /ScoopCloud/ -- Boothwyn Pharmacy, a PCAB-accredited compounding pharmacy located mere minutes from the heart of Kennett Square, Pennsylvania, has dedicated resources to manufacture hand sanitizer.
EPIC Continues Expansion of Employee Benefits Practice with a new Pharmacy Practice Leader
NEW YORK, N.Y. /ScoopCloud/ -- EPIC Insurance Brokers and Consultants, a retail property, casualty insurance brokerage and employee benefits consultant, announced today they are continuing to expand their employee benefits resources with the addition of a new Pharmacy Practice Leader, Bob Eisendrath.
iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting
STONY BROOK, N.Y. /ScoopCloud/ -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.
American Medical Marijuana Physicians Association’s 2019 Annual Meeting Hosted Over 300 Attendees and Physicians
ORLANDO, Fla. /ScoopCloud/ -- The American Medical Marijuana Physicians Association (AMMPA) held their 3rd Annual Conference on October 4-6 at the Hilton Orlando Lake Buena Vista. More than 300 medical marijuana practitioners and physicians from across the nation and other countries around the world attended the 3-day conference.
C Diff Foundation Raises Clostridioides difficile Awareness in St. Louis on Nov. 6-7 at 7th Annual International Conference and Health EXPO
ST. LOUIS, Mo. /ScoopCloud/ -- C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies. November 6 - 7, 2019 at the DoubleTree by Hilton Westport Hotel.
BioAdaptives, Inc. Announces Return to Fully Reporting and Appointment of President
LAS VEGAS, Nev. /ScoopCloud/ -- BioAdaptives, Inc. (OTC BB: BDPT) announced the Company's return to a fully-reporting entity, and the appointment of Mr. Robert W. Ellis as its new President, reporting to Dr. Edward E. Jacobs, Jr.
2019 Lupus Insight Prize Awarded to Dr. Ignacio Sanz: Recognizes Studies of Harmful Immune Cells in Lupus
BOSTON, Mass. /ScoopCloud/ -- The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors determine which patients could benefit from current drugs.